Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-β concentrations and cognition outcomes in Alzheimer’s disease patients: a multicenter, randomized, controlled clinical trial

Manuscript Number: 

16-0565R1

Author(s): 
Montserrat Alegret, Fernando Anaya, Mercè Boada, Mar Buendía, Isidre Ferrer, Joan Ramon Grifols, Isabel Hernández, Asunción Lafuente, Oscar Lopez, Joan Muñoz, Laura Núñez, Thomas O. Obisesan, Javier Olazarán, Pilar Ortiz, Antonio Páez, Joshua R. Shua-Haim, Mireia Torres, Lluís Tárraga

Disclosures

Montserrat Alegret

  • Nothing to Disclose

Fernando Anaya

  • Nothing to Disclose

Mercè Boada

  • Consulting Fees:
    Dr. M. Boada has consulted for Araclon, Avid, Bayer, Elan, Grifols, Janssen/Pfizer, Lilly, Neuroptix, Nutricia, Roche, Sanofi and Servier.
    Lecture Fees:
    She received fees for lectures and funds for research from Araclon, Esteve, Grifols, Janssen, Novartis, Nutricia, Piramal, Pfizer-Wyett, Roche and Servier.
    Grants
    • Agency: 
      EFSD - European Foundation for the Study of Diabetes. EFSD/Lilly Mental Health and Diabetes Programme.
      Dates: 
      2014-2015

Mar Buendía

  • Nothing to Disclose

Isidre Ferrer

  • Nothing to Disclose

Joan Ramon Grifols

  • Nothing to Disclose

Isabel Hernández

  • Nothing to Disclose

Asunción Lafuente

  • Nothing to Disclose

Oscar Lopez

  • Consulting Fees:
    Consultant for Grifols and Lundbeck

Joan Muñoz

  • Nothing to Disclose

Laura Núñez

  • Sponsors:
    Employee of Grifols Clinical Department

Thomas O. Obisesan

  • Nothing to Disclose

Javier Olazarán

  • Nothing to Disclose

Pilar Ortiz

  • Nothing to Disclose

Antonio Páez

  • Sponsors:
    Employee of Grifols Clinical Department

Joshua R. Shua-Haim

  • Nothing to Disclose

Lluís Tárraga

  • Nothing to Disclose

Mireia Torres

  • Sponsors:
    Employee of Grifols clinical Department